ZA201908264B - Formulations of homotaurines and salts thereof - Google Patents

Formulations of homotaurines and salts thereof

Info

Publication number
ZA201908264B
ZA201908264B ZA2019/08264A ZA201908264A ZA201908264B ZA 201908264 B ZA201908264 B ZA 201908264B ZA 2019/08264 A ZA2019/08264 A ZA 2019/08264A ZA 201908264 A ZA201908264 A ZA 201908264A ZA 201908264 B ZA201908264 B ZA 201908264B
Authority
ZA
South Africa
Prior art keywords
homotaurines
formulations
salts
Prior art date
Application number
ZA2019/08264A
Other languages
English (en)
Inventor
Steven Johns
Kenneth Payie
Badrinath Doniparthi
Original Assignee
Confluence Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Pharmaceuticals Llc filed Critical Confluence Pharmaceuticals Llc
Publication of ZA201908264B publication Critical patent/ZA201908264B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2019/08264A 2017-05-17 2019-12-11 Formulations of homotaurines and salts thereof ZA201908264B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507532P 2017-05-17 2017-05-17
US201862660690P 2018-04-20 2018-04-20
PCT/US2018/033205 WO2018213589A1 (en) 2017-05-17 2018-05-17 Formulations of homotaurines and salts thereof

Publications (1)

Publication Number Publication Date
ZA201908264B true ZA201908264B (en) 2022-03-30

Family

ID=64274653

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/08264A ZA201908264B (en) 2017-05-17 2019-12-11 Formulations of homotaurines and salts thereof

Country Status (8)

Country Link
US (1) US12042566B2 (https=)
EP (1) EP3624788A4 (https=)
JP (2) JP2020519669A (https=)
KR (1) KR20200005576A (https=)
AU (2) AU2018269557B2 (https=)
IL (1) IL270654B2 (https=)
WO (1) WO2018213589A1 (https=)
ZA (1) ZA201908264B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
WO2025163673A1 (en) * 2024-01-29 2025-08-07 Micro Labs Limited Dose-dumping resistant tablets of acamprosate calcium

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01280192A (ja) 1988-10-25 1989-11-10 Nichibei Co Ltd ブラインド内装サッシ
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
DE1073432T1 (de) 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
WO2000018374A1 (en) 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20050042277A1 (en) 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
CA2504471A1 (en) * 2004-06-18 2005-12-18 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
JP2010532331A (ja) 2007-07-05 2010-10-07 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 抗痙攣医薬組成物
CA2781830C (en) 2009-02-12 2018-03-27 Indiana University Research & Technology Corporation Materials and methods for treating developmental disorders including comorbid and idiopathic autism
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9195775B2 (en) 2009-06-26 2015-11-24 Iii Holdings 2, Llc System and method for managing and/or rendering internet multimedia content in a network
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
MX346203B (es) * 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
TR201809351T4 (tr) 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
DK3272342T3 (da) 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
JP5893135B2 (ja) 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2013293167B2 (en) 2012-07-22 2019-04-18 Indiana University Research And Technology Corporation Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD
US20140073678A1 (en) 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
SG11201708393UA (en) * 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate
HK1255584A1 (zh) 2015-08-04 2019-08-23 Confluence Pharmaceuticals, Llc 使用阿坎酸及d-环丝胺酸的联合疗法
JP6066009B1 (ja) 2016-06-16 2017-01-25 富士電機株式会社 ガス絶縁開閉装置用操作器及びそれを用いたガス絶縁開閉装置
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof

Also Published As

Publication number Publication date
JP7499539B2 (ja) 2024-06-14
EP3624788A4 (en) 2021-03-03
AU2021225172B2 (en) 2023-04-06
IL270654B2 (en) 2024-07-01
US20200163895A1 (en) 2020-05-28
US12042566B2 (en) 2024-07-23
IL270654A (en) 2020-01-30
AU2018269557B2 (en) 2021-06-03
KR20200005576A (ko) 2020-01-15
JP2020519669A (ja) 2020-07-02
EP3624788A1 (en) 2020-03-25
IL270654B1 (en) 2024-03-01
WO2018213589A1 (en) 2018-11-22
JP2023099100A (ja) 2023-07-11
CA3062834A1 (en) 2018-11-22
AU2021225172A1 (en) 2021-09-30
AU2018269557A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
ZA201905677B (en) Glycan-interacting compounds and methods of use
ZA201805805B (en) Formulations and methods
IL253526B (en) Oral treatment compounds and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
IL285928A (en) Fulvestrant formulations and methods of using them
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
PL3474822T3 (pl) Preparaty brincydofowiru
IL266132B (en) Pharmaceutical formulations and methods for their preparation
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
IL272857A (en) Cofanalisib formulations
IL274433A (en) Fulvestrant formulations and methods of using them
IL267279A (en) Pharmaceutical formulations of suvorexant
ZA201908264B (en) Formulations of homotaurines and salts thereof
PL3429555T3 (pl) Preparat mesny i jego zastosowanie
IL261794A (en) Preparations and methods for using them
PT3664800T (pt) Formulações terapêuticas que compreendem inibidor da cox-2 e utilizações das mesmas
PT3471835T (pt) Utilização de extratos de deschampsia antarctica para combater danos na barreira cutânea humana provocados por agressões ambientais
SG11201708527RA (en) Manufacture of organopolysulfides and salts thereof
HK40025148A (en) Formulations of homotaurines and salts thereof
IL264898A (en) Formulations of cysteamine and its derivatives
GB201716745D0 (en) New formulations and uses thereof
ZA201606358B (en) Compositions of selenoorganic compounds and methods and methods of use thereof